RZLT
Rezolute, Inc.
Biotechnology
Market Cap$300M
5Y Perf.-11.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RZLT vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.55B
5Y Perf.-62.1%
RZLT vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RZLT | RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $300M | $2.55B |
| Revenue (TTM) | $0.00 | $669M |
| Net Income (TTM) | $-84M | $-609M |
| Gross Margin | — | 83.6% |
| Operating Margin | — | -83.9% |
| Total Debt | $2M | $1.28B |
| Cash & Equiv. | $94M | $434M |
RZLT vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RZLT
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Rezolute, Inc. (RZLT) | 100 | 88.5 | -11.5% |
| Ultragenyx Pharmace… (RARE) | 100 | 37.9 | -62.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RZLT vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RZLT leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Ultragenyx Pharmaceutical Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
RZLT
Rezolute, Inc.
The Income Pick
RZLT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.79
- EPS growth 26.3%
- Lower volatility, beta 0.79, Low D/E 1.0%, current ratio 14.37x
Best for: income & stability and growth exposure
RARE
Ultragenyx Pharmaceutical Inc.
The Long-Run Compounder
RARE is the clearest fit if your priority is long-term compounding.
- -58.9% 10Y total return vs RZLT's -93.5%
- 20.1% revenue growth vs RZLT's -18.4%
- -45.8% ROA vs RZLT's -60.8%, ROIC -89.4% vs -97.9%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RARE | 20.1% revenue growth vs RZLT's -18.4% |
| Quality / Margins | RZLT | 3.1% margin vs RARE's -91.0% |
| Stability / Safety | RZLT | Beta 0.79 vs RARE's 1.42 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RZLT | -16.5% vs RARE's -26.0% |
| Efficiency (ROA) | RARE | -45.8% ROA vs RZLT's -60.8%, ROIC -89.4% vs -97.9% |
RZLT vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
RZLT vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRZLTLAGGINGRARE
RAREUltragenyx Pharmaceut…
1leads
RZLTRezolute, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs RAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RZLT1/1
Valuation MetricsMultiples, price ratios, and targets
RARE1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
RZLT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RZLT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RARE and RZLT operate at a comparable scale, with $669M and $0 in trailing revenue.
| Metric | RZLTRezolute, Inc. | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $669M |
| EBITDAEarnings before interest/tax | -$64M | -$536M |
| Net IncomeAfter-tax profit | -$84M | -$609M |
| Free Cash FlowCash after capex | -$77M | -$487M |
| Gross MarginGross profit ÷ Revenue | — | +83.6% |
| Operating MarginEBIT ÷ Revenue | — | -83.9% |
| Net MarginNet income ÷ Revenue | — | -91.0% |
| FCF MarginFCF ÷ Revenue | — | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | 0.0% | -17.2% |
RZLT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
RARE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | RZLTRezolute, Inc. | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $300M | $2.5B |
| Enterprise ValueMkt cap + debt − cash | $208M | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -3.20x | -4.45x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3.79x |
| Price / BookPrice ÷ Book value/share | 1.47x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
RARE leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
Evenly matched — RZLT and RARE each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
RZLT delivers a -65.8% return on equity — every $100 of shareholder capital generates $-66 in annual profit, vs $-6 for RARE.
| Metric | RZLTRezolute, Inc. | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | -65.8% | -6.1% |
| ROA (TTM)Return on assets | -60.8% | -45.8% |
| ROICReturn on invested capital | -97.9% | -89.4% |
| ROCEReturn on capital employed | -55.7% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.01x | — |
| Net DebtTotal debt minus cash | -$92M | $842M |
| Cash & Equiv.Liquid assets | $94M | $434M |
| Total DebtShort + long-term debt | $2M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | — | -14.49x |
Evenly matched — RZLT and RARE each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
RZLT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RZLT five years ago would be worth $4,538 today (with dividends reinvested), compared to $2,241 for RARE. Over the past 12 months, RZLT leads with a -16.5% total return vs RARE's -26.0%. The 3-year compound annual growth rate (CAGR) favors RZLT at 10.5% vs RARE's -18.0% — a key indicator of consistent wealth creation.
| Metric | RZLTRezolute, Inc. | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | +45.0% | +9.9% |
| 1-Year ReturnPast 12 months | -16.5% | -26.0% |
| 3-Year ReturnCumulative with dividends | +34.8% | -44.9% |
| 5-Year ReturnCumulative with dividends | -54.6% | -77.6% |
| 10-Year ReturnCumulative with dividends | -93.5% | -58.9% |
| CAGR (3Y)Annualised 3-year return | +10.5% | -18.0% |
RZLT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RZLT and RARE each lead in 1 of 2 comparable metrics.
Risk & Volatility
RZLT is the less volatile stock with a 0.79 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RARE currently trades 61.2% from its 52-week high vs RZLT's 27.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RZLTRezolute, Inc. | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 1.42x |
| 52-Week HighHighest price in past year | $11.46 | $42.37 |
| 52-Week LowLowest price in past year | $1.07 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +27.4% | +61.2% |
| RSI (14)Momentum oscillator 0–100 | 51.7 | 61.0 |
| Avg Volume (50D)Average daily shares traded | 2.2M | 1.8M |
Evenly matched — RZLT and RARE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RZLT as "Buy" and RARE as "Buy". Consensus price targets imply 101.6% upside for RZLT (target: $6) vs 98.6% for RARE (target: $52).
| Metric | RZLTRezolute, Inc. | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $6.33 | $51.50 |
| # AnalystsCovering analysts | 12 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RZLT leads in 2 of 6 categories (Income & Cash Flow, Total Returns). RARE leads in 1 (Valuation Metrics). 2 tied.
Best OverallRezolute, Inc. (RZLT)Leads 2 of 6 categories
Loading custom metrics...
RZLT vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RZLT or RARE a better buy right now?
Analysts rate Rezolute, Inc.
(RZLT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RZLT or RARE?
Over the past 5 years, Rezolute, Inc.
(RZLT) delivered a total return of -54. 6%, compared to -77. 6% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: RARE returned -58. 9% versus RZLT's -93. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RZLT or RARE?
By beta (market sensitivity over 5 years), Rezolute, Inc.
(RZLT) is the lower-risk stock at 0. 79β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 80% more volatile than RZLT relative to the S&P 500.
04Which is growing faster — RZLT or RARE?
On earnings-per-share growth, the picture is similar: Rezolute, Inc.
grew EPS 26. 3% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RZLT or RARE?
Rezolute, Inc.
(RZLT) is the more profitable company, earning 0. 0% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RZLT leads at 0. 0% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RZLT or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RZLT or RARE better for a retirement portfolio?
For long-horizon retirement investors, Rezolute, Inc.
(RZLT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 79)). Both have compounded well over 10 years (RZLT: -93. 5%, RARE: -58. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RZLT and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RZLT is a small-cap quality compounder stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.